RSS   Newsletter   Contact   Advertise with us
Post Online Media

Valeant appoints Richard U. DeSchutter as director

ValeantValeant Pharmaceuticals International announced that it has elected Richard U. DeSchutter to serve as a director.

Prior to his retirement, Mr. DeSchutter served as the Chairman and Chief Executive Officer of DuPont Pharmaceuticals Company from July 2000 until its acquisition by Bristol-Myers Squibb in October 2001.

Article continues below

READ MORE Valeant appoints Paul Herendeen as EVP, finance and CFO

Prior to DuPont, Mr. DeSchutter was a Director and Chief Administrative Officer of Pharmacia Corporation, which was created through the merger of Monsanto Company and Pharmacia & Upjohn in 2000.

Prior to the merger, he was a Director, Vice Chairman and Chief Administrative Officer for Monsanto. From 1995 to 1999, he served as Chairman and CEO of G.D. Searle & Co., Monsanto's wholly owned pharmaceutical subsidiary.

Mr. DeSchutter currently serves as a director of AuVen Therapeutics and Applied Silver, Inc.

He was previously Chairman of Incyte Corporation (2003 to 2015); Durata Therapeutics Inc. (2012 to 2014); and Lead Independent Director (2011 to 2014) and Director (2001 to 2014) of Smith & Nephew plc.

Mr. DeSchutter earned a Bachelor of Science degree (1962) and a Master of Science Degree (1963) in Chemical Engineering from the University of Arizona.




What to read next



 LATEST MOVES FROM Quebec 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy